Alvine Pharmaceuticals, Inc., a biopharmaceutical company which focuses on the treatment of gastrointestinal and autoimmune diseases, has been issued four key patents by the United States Patent and Trademark Office. Patents 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protect key pieces of Alvine’s core technology. These patents cover gluten degradation with gluten-specific proteases, methods for identifying proteases useful in degrading gluten and reagents for diagnosing celiac disease. Alvine Pharmaceuticals, Inc. has a globally exclusive license to these patents from Stanford University.
“The issuance of these patents is a significant achievement for Alvine as they provide further intellectual property protection for the company’s protease development program,” said Abhay Joshi, Ph.D., Alvine’s President and Chief Executive Officer. “With our strong patent portfolio and ongoing clinical trials of ALV003, Alvine is building a strong foundation for the successful development of proteases as potential therapeutic agents.”
What is ALV003? ALV003 is a mixture of two proteases that have been recombined and engineered to cause degrading of gluten into non-immunogenic peptide fragments. ALV003 is being developed as a potential treatment for persons afflicted with Celiac Disease. At this time, ALV003 is designed to be administered orally.
Celiac Disease is a common hereditary autoimmune disease potentially affecting as many as 1-2% of all persons in the United States and European Union. Currently, the only available treatment for Celiac Disease is strict adherence to a gluten-free diet.
For more information, go to Alvine Pharmaceuticals – News and Media – Press Releases